<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816972</url>
  </required_header>
  <id_info>
    <org_study_id>P04258</org_study_id>
    <nct_id>NCT00816972</nct_id>
  </id_info>
  <brief_title>Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)</brief_title>
  <official_title>Pilot Efficacy and Safety Field Trial of Desloratadine Administered Concomitantly With Oxybutynin, in Subjects With Seasonal Allergic Rhinitis and Post-Nasal Drip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a 1-week study of desloratadine (DL) plus oxybutynin (OXY) at two dose levels in the
      treatment of post-nasal drip in participants with seasonal allergic rhinitis. Participants
      received either desloratadine twice a day, oxybutynin twice a day, desloratadine plus
      lower-dose oxybutynin twice a day, desloratadine plus higher-dose oxybutynin twice a day, or
      placebo for 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean daily AM/PM Prior post-nasal drip scores averaged over the entire treatment period</measure>
    <time_frame>Days 1 to 7 +/- 2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anterior rhinorrhea averaged over Days 1 to 8</measure>
    <time_frame>Days 1 to 8</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">540</enrollment>
  <condition>Post-nasal Drip</condition>
  <condition>Seasonal Allergic Rhinitis</condition>
  <condition>Rhinorrhea</condition>
  <arm_group>
    <arm_group_label>DL 2.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Desloratadine 2.5 mg twice daily (BID) + Placebo for Oxybutynin 2.5 mg BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OXY 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo for Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DL 2.5 mg + OXY 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desloratadine 2.5 mg BID + Oxybutynin 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DL 2.5 mg + OXY 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Desloratadine 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine 2.5 mg</intervention_name>
    <description>Desloratadine 2.5 mg BID</description>
    <arm_group_label>DL 2.5 mg</arm_group_label>
    <arm_group_label>DL 2.5 mg + OXY 2.5 mg</arm_group_label>
    <arm_group_label>DL 2.5 mg + OXY 5 mg</arm_group_label>
    <other_name>SCH 034117</other_name>
    <other_name>Clarinex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin 2.5 mg</intervention_name>
    <description>Oxybutynin 2.5 mg BID</description>
    <arm_group_label>OXY 5 mg</arm_group_label>
    <arm_group_label>DL 2.5 mg + OXY 2.5 mg</arm_group_label>
    <arm_group_label>DL 2.5 mg + OXY 5 mg</arm_group_label>
    <other_name>Ditropan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Desloratadine 2.5 mg</intervention_name>
    <description>Placebo BID</description>
    <arm_group_label>OXY 5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Oxybutynin 2.5 mg</intervention_name>
    <description>Placebo BID</description>
    <arm_group_label>DL 2.5 mg</arm_group_label>
    <arm_group_label>DL 2.5 mg + OXY 2.5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must:

          -  be &gt;=18 years of age,

          -  be free of any clinically significant disease that would interfere with study, other
             than seasonal allergic rhinitis (SAR),

          -  have a documented diagnosis of SAR for &gt;=2 years,

          -  have had a positive skin-prick test,

          -  be sufficiently symptomatic at the Screening visit,

          -  for the 3 calendar days immediately prior to baseline visit, plus the AM of the
             baseline visit, the seven twice-daily run-in diary PRIOR total nasal symptom scores
             must have totaled &gt;=42, the Total Non-Nasal Symptoms score must have totaled &gt;=28, and
             the total Post Nasal Drip score must have totaled &gt;=14,

          -  be in general good health.

        Exclusion Criteria:

        Subjects who have:

          -  certain medical conditions or medical histories,

          -  allergies to any of the components in any of the study medications,

          -  nasal structure abnormalities,

          -  dependency to nasal, oral, or ocular decongestants, nasal topical antihistamines, or
             nasal steroids,

          -  used any investigational drug use in past 30 days,

          -  received immunotherapy (desensitization)

          -  are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2009</study_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

